I am basically a huge nerd and proud of that fact. Ten years ago, I moved from advertising and marketing into management consultancy and service design, focusing on innovation, digital strategy and commercialisation, working with health, government and education clients at a State and Federal level. I have worked as a C-level executive at an ASX listed SaMD company and also co-founded a health-tech start up and built it from scratch, navigating the company through investment and commercialisation. Supporting this, my experience spans human-centred design, operations, brand strategy, visual communication and design, product ownership / management, and marketing and communications. I have worked across almost every industry and for every sort of company (from start ups to multinationals), however my passion now lies in innovation, service design, digital transformation and commercialisation from an operational and leadership perspective — embedding innovation as a core business competency in STEM organisations and developing high quality, impact driven and fun teams. I am the Innovation Manager at Commercial Eyes, responsible for driving and managing innovation initiatives and services offerings related to market access, market research and market intelligence of Commercial Eyes.

Maree Beare is a visionary leader in the HealthTech industry, known for her pioneering work in leveraging AI to transform clinical trials operations, creating Clinials an AI-powered document assistant designed to streamline global clinical trial operations generating clinical trial documents in minutes, freeing up clinicians and research teams to enable an increased focus on patients, humans, rather than paperwork. Clinials streamlines global clinical trial operations by: 🚀 Reducing protocol review time by 70%, trial startup halved 📄 Automating clinical trial document generation, such as protocol summaries and patient information sheets 🌍 Providing multilingual content & interactive trial schedules 💡 Enhancing communication & engagement with stakeholders Maree’s work has been widely recognized. She was named one of Forbes’ Top 50 Women-Led Startups Disrupting HealthTech and featured as a FemTech leader in the FemTech Industry Landscape Overview 2021. Under her leadership, Clinials was listed among StartUs Insights’ Top 10 AI Trends in Healthcare for 2023. She is a passionate advocate for AI-driven solutions that improve health outcomes, foster innovation, and ensure inclusivity in healthcare and clinical research. Maree’s inspiring leadership and groundbreaking work continue to shape the future of HealthTech and Biotech, making her a sought-after speaker on AI in healthcare, clinical trials innovation, and the intersection of technology and patient-centric care.

Chelsea Gordon is the AI Advisory Legal Lead at MinterEllison and is at the forefront of AI regulation. Chelsea is also an experienced health and life sciences lawyer, with expertise in clinical trials, health service regulation and therapeutic goods. Chelsea specialises in Responsible AI and works to enable her clients to maximise the opportunities presented by AI, whilst mitigating legal risks. Chelsea has recently advised some of Australia's largest private and public healthcare service providers about the privacy, intellectual property and related legal risks associated with AI, whilst supporting them to build fit-for-purpose frameworks that are solutions – oriented.

Saurabh Jain is a seasoned leader in technology and healthcare, currently serving as the Executive Chairman of Opyl, a publicly listed company at the forefront of AI-assisted technologies for the healthcare sector. He spearheads Opyl's mission to empower leading biopharma and health organizations with innovative solutions and expert guidance using TrialKey. TrialKey delivers expert‑led, clinically grounded AI trial design. Practicing specialists in drug safety, patient care, pharmacology, clinical operations and biostatistics guide each step, from model training to recommendation review. A proprietary dataset spanning 520 000 studies, 2.69 billion patients and expanded outcome records feeds explainable models such as XGBoost and Random Forests that optimise 1 500 variables. The platform then issues clear directions on protocol rules, site selection, resource allocation and competitor positioning, cutting timelines and lifting success rates. Speak with a TrialKey specialist to apply these insights to your next study.